About this journal

Aims and scope

Pharmaceutical Development & Technology is a subscription-based, peer-reviewed journal that publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology.

Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as:

  • Preformulation and pharmaceutical formulation studies
  • Pharmaceutical materials selection and characterization
  • Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation
  • QbD in the form a risk assessment and DoE driven approaches
  • Design of dosage forms and drug delivery systems
  • Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies
  • Drug delivery systems research and quality improvement
  • Pharmaceutical regulatory affairs

This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.

The journal's audience includes:

  • Academic Researchers: Individuals involved in pharmaceutical research and development at universities and colleges.
  • Industry Professionals: Experts working in the pharmaceutical industry, including formulation scientists, process engineers and quality assurance specialists.
  • Healthcare Practitioners: Medical professionals interested in the latest advancements in drug delivery and pharmaceutical technologies.
  • Policy Makers: Regulatory authorities and policy makers who oversee pharmaceutical practices and standards.

All articles received by the Journal will be subject to single-anonymous peer review. 

Journal metrics

Usage

  • 109K annual downloads/views

Citation metrics

  • 2.6 (2023) Impact Factor
  • Q2 Impact Factor Best Quartile
  • 3.1 (2023) 5 year IF
  • 5.9 (2023) CiteScore (Scopus)
  • Q2 CiteScore Best Quartile
  • 0.609 (2023) SNIP
  • 0.476 (2023) SJR

Speed/acceptance

  • 22 days avg. from submission to first decision
  • 63 days avg. from submission to first post-review decision
  • 13 days avg. from acceptance to online publication
  • 15% acceptance rate

Editorial board

EDITOR IN CHIEF

Professor Raid Alany
Kingston University
London
UK

SOCIAL MEDIA EDITORS

Ali Al-Kinani - Kingston University, UK
Arushi Manchanda - University of Connecticut, USA

BOOK REVIEW EDITOR

Harry Brittain - Center for Pharmaceutical Physics, Milford, NJ, USA

EDITORIAL BOARD

Zeeshan Ahmad - De Montfort University, Leicester, UK
Professor Göran Alderborn - Uppsala University Department of Pharmacy, Uppsala, Sweden
Professor Robin H. Bogner - University of Connecticut School of Pharmacy, Connecticut, USA
Dr.Gayle Brazeau - University of New England, Portland, ME, USA
Professor Craig Bunt - Lincoln University, Canterbury, New Zealand
Professor Carla Caramella - Universita degli Studi di Pavia, Pavia, Italy
Dr.Metin Celik - Pharmaceutical Technology International, Inc., Belle Meade, NJ, USA
Professor Yahya Choonara - University of the Witwatersrand, Johannesburg, South Africa
Professor/Dr. Tansel Çomoglu - Ankara University, Ankara, Turkey
Todd Darrington - Millennium Pharmaceuticals, Boston, MA, USA
Professor Gillian Eccleston - University of Strathclyde, Glasgow, Scotland, UK
David Friend - CONRAD, Arlington, VA, USA
Professor/Dr. Wolfgang Friess - Ludwig-Maximillians-Universitat, München, Germany
Professor/Dr. HW Frijlink - Groningen University, Groningen, Netherlands
Larry Gatlin - Consultant, Groton, CT, USA
Dr.Wayne Gombotz - Immune Design, Seattle, WA, USA
Associate Professor - Holger Grohganz - University of Copenhagen, Copenhagen, Denmark
Dr. Pramod Gupta - Spectrum, Irvine, CA, USA
Paul Heng - National University of Singapore, Singapore
Dr. Anthony Hickey - RTI International, Research Triangle Park, NC, USA
Professor Stephen Hoag - University of Maryland, Baltimore, MD, USA
Lars Hovgaard - Novo-Nordisk, Copenhagen Denmark
Munir Hussain - Bristol-Myers Squibb, New Brunswick, NJ, USA
Dr. Gerald Kasting - University of Cincinnati, Cincinnati, OH, USA
Professor Peter Kleinebudde - Heinrich-Heine-University, Düsseldorf, Germany
Jim Kou - Impax Labs, Hayward, CA, USA
Michael Leane - Bristol-Myers Squibb, Moreton, UK
Professor Kang Choon Lee - Sung Kyun Kwan University, Suwon City, South Korea
Professor Ping Lee - University of Toronto, Ontario, Canada
John Ludwig - Pfizer, Chesterfield, MO, USA
Dr. Rouslan I. Moustafine - Kazan State Medical University,Tatarstan, Russian Federation
Professor/Dr. Bernd Muller - Pharmazeutisches Institute, Kiel, Germany
Dr. Steve Nail - Baxter BioPharma Solutions, Bloomington, IN, USA
Professor/Dr. Ali Nokhodchi - University of Sussex, Brighton, UK
Katharina Picker-Freyer - Martin-Luther-Universitat, Halle/Saale, Germany
Stuart Porter - Hatfield, PA , USA
Dr. Omar Qutachi - De Montfort University, Leicester, UK
Professor Jukka Rantanen - University of Copenhagen, Copenhagen, Denmark
Professor/Dr. Jean-Paul Remon - Ghent University, Ghent, Belgium
Dr. Michael Repka - University of Mississippi, Oxford, MS, USA
Frantisek Rypacek - Institute of Macromolecular Chemistry, Prague, Czech Republic
Professor/Dr. Adel Sakr - Future University, New Cairo, Egypt
Dr. Claudio J Salomon - National University of Rosario, Rosario, Argentina
Professor Sevda Senel - Hacettepe Universtiy Faculty of Pharmacy, Ankara, Turkey
Professor Ali Seyfoddin - Auckland University of Technology, Auckland, New Zealand
Professor Jagdish Singh - North Dakota State University, Fargo, ND, USA
Paul J Sirois - Eli Lily and Company, Indianapolis, IN, USA
Dr. Eliana B. Souto - University of Coimbra, Porto, Portugal
Gregory A. Stephenson - Eli Lilly and Company, Indianapolis, IN, USA
Dr. Lynne Taylor - Purdue University, West Lafayette, IN, USA
Curt Thies- Thies Techology, Inc., Henderson, NV, USA
Dr. Mike Tobyn - Bristol-Myers Squibb, Moreton, England, UK
Dr. Thilini Thrimawithana - RMIT University, Melbourne, Australia
Murat Turkoglu - Markim Cosmetic Consultancy, Istanbul, Turkey
Ken Walters - The Old Coach House, Spraxton, UK
Dr. Ken Waterman - FreeThink Technologies, East Lyme, CT, USA
Dr. Zimei Wu - The University of Auckland School of Pharmacy, Auckland, New Zealand


Updated 02/07/24

Abstracting and indexing

id="_ctl0_ContentPlaceHolder1_HeaderDetails1_lblJournalTitle"> Pharmaceutical Development and Technology is included in the following abstracting and indexing services:

Biotechnology Abstracts; Business Source Corporate; Chemical Abstracts; Derwent Chimera; Derwent Drug File; International Pharmaceutical Abstracts; EMBASE; Journal Citation Reports/Science Edition; PASCAL; PopLine; PubMed/MedLine; SciSearch; SCOPUS.

Open access

Pharmaceutical Development and Technology is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.

Why choose open access?

  1. Increase the discoverability and readership of your article
  2. Make an impact and reach new readers, not just those with easy access to a research library
  3. Freely share your work with anyone, anywhere
  4. Comply with funding mandates and meet the requirements of your institution, employer or funder
  5. Rigorous peer review for every open access article

Article Publishing Charges (APC)

If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.

Use our APC finder to calculate your article publishing charge

Advertising information

Would you like to advertise in Pharmaceutical Development and Technology?

Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Pharmaceutical Development and Technology.

Explore advertising solutions

Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .

Ready to submit?

Start a new submission or continue a submission in progress

Go to submission site (link opens in a new window) Instructions for authors